The occurance and prevalence of multidrug-resistant tuberculosis poses a serious threat to the global tuberculosis control. Ethambutol (EMB) is one of the first-line anti-tuberculosis drugs, which is usually used in combination with isoniazid and rifampicin for treating pan-sensitive tuberculosis, and it can also be used in drug-resistant tuberculosis. However, the situation of EMB resistance is alarmingly high, especially in multi-drug resistant tuberculosis. In China, EMB resistance rate in the previously treated cases was up to 17.2% and showed an increased tendency. What was worse, 51.3%-66.7% of multidrug-resistant tuberculosis cases were resistant to EMB. Thus, it is important to understand the drug resistance mechanism of EMB, which will help to slow down the drug resistance rate of EMB. In this review, we focus on the current status of EMB resistance, the effects of EMB and the mechanisms of EMB resistance in Mycobacterium tuberculosis.
[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[2] He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, Wang LX, Borgdorff MW, van der Werf MJ, van den Hof S. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis , 2008, 8(1): 166.
[3] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170.
[4] Gonzalo X, Hutchison DC, Drobniewski FA, Pimkina E, Davidaviciene E. Multidrug-resistant tuberculosis in the United Kingdom and Lithuania. Int J Tuberc Lung Dis , 2014, 18(6): 663-665.
[5] Zhang ZJ, Wang YG, Pang Y, Kam KM. Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol , 2014, 52(2): 638-641.
[6] Chen QY, Pang Y, Liang QF, Lin SF, Wang YF, Lin J, Zhao Y, Wei SZ, Zheng JF, Zheng SH. Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian, China. Tuberculosis , 2014, 94(2): 159-161.
[7] Shi DW, Li L, Zhao YL, Jia Q, Li H, Coulter C, Jin Q, Zhu GF. Characteristics of embB mutations in multidrug- resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother , 2011, 66(10): 2240-2247.
[8] Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol , 1997, 1(4): 579-588.
[9] Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol , 2012, 7(1): 129-147.
[10] Srivastava S, Ayyagari A, Dhole TN, Nyati KK, Dwivedi SK. emb nucleotide polymorphisms and the role of embB 306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol , 2009, 299(4): 269-280.
[11] Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother , 2000, 44(2): 326-336.
[12] Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis , 2007, 87(2): 123-129.
[13] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol , 2002, 40(10): 3810-3813.
[14] Hazbón MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, Davidow A, Brimacombe M, León CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de León A, Cave MD, Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS 6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother , 2005, 49(9): 3794-3802.
[15] Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol , 2002, 40(11): 3976-3979.
[16] Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother , 2008, 52(6): 2027-203
